The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers
Open accessAbstract
Introduction Functions of cancer progenitor cells in the cancer initiation and progression New model of carcinogenesis based on the cancer progenitor cells Isolation and ex vitro and in vivo characterization of functional properties of cancer progenitor cells Functions of cancer progenitor cells in the cancer development Influence of local tumour microenvironment on the behavior of cancer progenitor cells Cancer types originating from cancer progenitor cells New concepts of the heterogeneity of cancers derived from distinct cancer progenitor cells Implication of cancer progenitor cells in bone marrow‐derived cancers Leukaemias Sarcomas Implication of cancer progenitor cells in pediatric and adult brain tumors Implication of cancer progenitor cells in other cancer types Novel cancer therapies by molecular targeting of cancer progenitor cells and their microenvironment New concepts on the functions of cancer progenitor cells in the resistance to current cancer therapies New combination therapies against the aggressive and recurrent cancers Targeting cancer progenitor cells Targeting the local microenvironment of cancer progenitor cells Conclusions Future directions and perspectives Overcoming intrinsic and acquired resistance of cancer stem/progenitor cells to current clinical treatments represents a major challenge in treating and curing the most aggressive and metastatic cancers. This review summarizes recent advances in our understanding of the cellular origin and molecular mechanisms at the basis of cancer initiation and progression as well as the heterogeneity of cancers arising from the malignant transformation of adult stem/progenitor cells. We describe the critical functions provided by several growth factor cascades, including epidermal growth factor receptor (EGFR), platelet‐derived growth factor receptor (PDGFR), stem cell factor (SCF) receptor (KIT), hedgehog and Wnt/β ‐catenin signalling pathways that are frequently activated in cancer progenitor cells and are involved in their sustained growth, survival, invasion and drug resistance. Of therapeutic interest, we also discuss recent progress in the development of new drug combinations to treat the highly aggressive and metastatic cancers including refractory/relapsed leukaemias, melanoma and head and neck, brain, lung, breast, ovary, prostate, pancreas and gastrointestinal cancers which remain incurable in the clinics. The emphasis is on new therapeutic strategies consisting of molecular targeting of distinct oncogenic signalling elements activated in the cancer progenitor cells and their local microenvironment during cancer progression. These new targeted therapies should improve the efficacy of current therapeutic treatments against aggressive cancers, and thereby preventing disease relapse and enhancing patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
Cancer stem cells: an old idea–a paradigm shift
Wicha, M. S., Liu, S., & Dontu, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3153 · Cited by 1,378
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
Blair, A., Hogge, D. E., Ailles, L. E., Lansdorp, P. M., & Sutherland, H. J. (1997) · Blood · doi:10.1182/blood.v89.9.3104 · Cited by 335
Dome, B., Timar, J., Dobos, J., Meszaros, L., Raso, E., Paku, S., Kenessey, I., Ostoros, G., Magyar, M., Ladanyi, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4654 · Cited by 184
Vascular endothelial growth factor (VEGF) inhibition—a critical review
Sousa Moreira, I., Alexandrino Fernandes, P., & Joao Ramos, M. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007780058687 · Cited by 110
Cited by
Exploring the role of cancer stem cells in radioresistance
Baumann, M., Krause, M., & Hill, R. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2419 · Cited by 815
“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?
Davis, A., Tinker, A. V., & Friedlander, M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.038 · Cited by 433
Cancer stem cell markers in common cancers – therapeutic implications
Klonisch, T., Wiechec, E., Hombach-Klonisch, S., Ande, S. R., Wesselborg, S., Schulze-Osthoff, K., & Los, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.08.003 · Cited by 393
Mimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 330
Self-citationPotential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
JIAPAER, S., FURUTA, T., TANAKA, S., KITABAYASHI, T., & NAKADA, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 324
Metadata
- Authors
- Mimeault, M., Hauke, R., Mehta, P. P., & Batra, S. K.
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2007-09
- Volume
- 11
- Issue
- 5
- Pages
- 981-1011
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- OpenAlex
- W2136441460
- Cited by
- 212
- References
- 12
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. https://app.cochat.ai/papers/10.1111/j.1582-4934.2007.00088.x
- The paper
- Mimeault, M., Hauke, R., Mehta, P. P., & Batra, S. K. (2007). Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2007.00088.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.